Vaccine immunity against fungal infections

Current Opinion in Immunology

Volumn 28, Issue 1, 2014, Pages 27-33

  Nanjappa, Som G ^a   Klein, Bruce S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPERGILLUS 16 F VACCINE; ASPERGILLUS 3 F VACCINE; CANDIDA ALBICANS VACCINE; CD8 ANTIGEN; CHAPERONIN 60; DIPHTHERIA TOXOID; FUNGUS VACCINE; GLUCURONOXYLOMANNAN; HEAT SHOCK PROTEIN; KEXIN; LAMINARAN; MANNOPROTEIN; NDV 3 VACCINE; PROTEIN P10; RPB27 VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ESOPHAGUS CANDIDIASIS; HISTOPLASMA; HISTOPLASMOSIS; IMMUNOGENICITY; LUNG MYCOSIS; MEMORY T LYMPHOCYTE; MYCOSIS; NONHUMAN; OROPHARYNX CANDIDIASIS; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; REVIEW; SOUTH AMERICAN BLASTOMYCOSIS; TH1 CELL; TH17 CELL; VAGINA CANDIDIASIS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FUNGAL VACCINES; HUMANS; IMMUNOLOGIC MEMORY; MYCOSES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84896857974     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.014     Document Type: Review

References (77)

1. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11:275-288.
2. Wuthrich M., Deepe G.S., Klein B. Adaptive immunity to fungi. Annu Rev Immunol 2012, 30:115-148.
3. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
4. Hernandez-Santos N., Huppler A.R., Peterson A.C., Khader S.A., McKenna K.C., Gaffen S.L. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol 2013, 6:900-910.
5. Ifrim D.C., Bain J.M., Reid D.M., Oosting M., Verschueren I., Gow N.A., van Krieken J.H., Brown G.D., Kullberg B.J., Joosten L.A., et al. The role of Dectin-2 for host defense against systemic infection with Candida glabrata. Infect Immun 2013, [Epub ahead of print].
6. Wuthrich M., Gern B., Hung C.Y., Ersland K., Rocco N., Pick-Jacobs J., Galles K., Filutowicz H., Warner T., Evans M., et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest 2011, 121:554-568.
7. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., Belladonna M.L., Vacca C., Conte C., Mosci P., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2695-2706.
8. Hung C.Y., Gonzalez A., Wuthrich M., Klein B.S., Cole G.T. Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17). Infect Immun 2011, 79:4511-4522.
9. Papon N., Courdavault V., Clastre M., Bennett R.J. Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog 2013, 9:e1003550.
10. Edwards J.E. Fungal cell wall vaccines: an update. J Med Microbiol 2012, 61:895-903.
11. Jolink H., Meijssen I.C., Hagedoorn R.S., Arentshorst M., Drijfhout J.W., Mulder A., Claas F.H., van Dissel J.T., Falkenburg J.H., Heemskerk M.H. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis 2013, 208:847-856.
12. Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M., Lurati S., Conrad B., Worschech E., Stevanovic S., et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011, 117:5881-5891.
13. Luong M., Lam J.S., Chen J., Levitz S.M. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007, 25:4340-4344.
14. Zheng M., Ramsay A.J., Robichaux M.B., Norris K.A., Kliment C., Crowe C., Rapaka R.R., Steele C., McAllister F., Shellito J.E., et al. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005, 115:3536-3544.
15. Feng Y., Guo S., Jiang T., Han X., Liu P., Wu T., Luo Y. Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats. Can J Microbiol 2011, 57:375-381.
16. Duan Y.N., Yi L.H., Chen J.L., Zhu D.D., Wang J.X., Feng J.R., Qin Y.W., Zhu Y. Protective effect of DNA vaccine with the gene encoding 55kDa antigen fragment against Pneumocystis carinii in mice. Asian Pac J Trop Med 2011, 4:353-356.
17. Scheckelhoff M., Deepe G.S. The protective immune response to heat shock protein 60 of Histoplasma capsulatum is mediated by a subset of V beta 8.1/8.2+ T cells. J Immunol 2002, 169:5818-5826.
18. Johnson S.M., Lerche N.W., Pappagianis D., Yee J.L., Galgiani J.N., Hector R.F. Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Ann N Y Acad Sci 2007, 1111:290-300.
19. Hurtgen B.J., Hung C.Y., Ostroff G.R., Levitz S.M., Cole G.T. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect Immun 2012, 80:3960-3974.
20. Mayorga O., Munoz J.E., Lincopan N., Teixeira A.F., Ferreira L.C., Travassos L.R., Taborda C.P. The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide. Front Microbiol 2012, 3:154.
21. Fernandes V.C., Martins E.M., Boeloni J.N., Coitinho J.B., Serakides R., Goes A.M. Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis. PLoS One 2011, 6:e17885.
22. de Bastos Ascenco Soares R., Gomez F.J., de Almeida Soares C.M., Deepe G.S. Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection. Infect Immun 2008, 76:4214-4221.
23. Miller R.F., Huang L., Walzer P.D. Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med 2013, 34:229-241.
24. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
25. Nacher M., Adenis A., Mc Donald S., Do Socorro Mendonca Gomes M., Singh S., Lopes Lima I., Malcher Leite R., Hermelijn S., Wongsokarijo M., Van Eer M., et al. Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. PLoS Negl Trop Dis 2013, 7:e2319.
26. Pupaibool J., Limper A.H. Other HIV-associated pneumonias. Clin Chest Med 2013, 34:243-254.
27. Kenyon C., Bonorchis K., Corcoran C., Meintjes G., Locketz M., Lehloenya R., Vismer H.F., Naicker P., Prozesky H., van Wyk M., et al. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 2013, 369:1416-1424.
28. Castellino F., Germain R.N. Cooperation between CD4(+) and CD8(+) T cells: when, where, and how. Annu Rev Immunol 2006, 24:519-540.
29. Wuthrich M., Filutowicz H.I., Warner T., Deepe G.S., Klein B.S. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 2003, 197:1405-1416.
30. Lindell D.M., Moore T.A., McDonald R.A., Toews G.B., Huffnagle G.B. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J Immunol 2005, 174:7920-7928.
31. Kolls J.K., Habetz S., Shean M.K., Vazquez C., Brown J.A., Lei D., Schwarzenberger P., Ye P., Nelson S., Summer W.R., et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J Immunol 1999, 162:2890-2894.
32. Fierer J., Waters C., Walls L. Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J Infect Dis 2006, 193:1323-1331.
33. Chiarella A.P., Arruda C., Pina A., Costa T.A., Ferreira R.C., Calich V.L. The relative importance of CD4+ and CD8+T cells in immunity to pulmonary paracoccidioidomycosis. Microbes Infect 2007, 9:1078-1088.
34. De Luca A., Iannitti R.G., Bozza S., Beau R., Casagrande A., D'Angelo C., Moretti S., Cunha C., Giovannini G., Massi-Benedetti C., et al. CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease. J Clin Invest 2012, 122:1816-1831.
35. Nanjappa S.G., Heninger E., Wuthrich M., Gasper D.J., Klein B.S. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 2012, 8:e1002771.
36. Wuthrich M., Warner T., Klein B.S. IL-12 is required for induction but not maintenance of protective, memory responses to Blastomyces dermatitidis: implications for vaccine development in immune-deficient hosts. J Immunol 2005, 175:5288-5297.
37. Nanjappa S.G., Heninger E., Wuthrich M., Sullivan T., Klein B. Protective antifungal memory CD8(+) T cells are maintained in the absence of CD4(+) T cell help and cognate antigen in mice. J Clin Invest 2012, 122:987-999.
38. McAllister F., Ruan S., Steele C., Zheng M., McKinley L., Ulrich L., Marrero L., Shellito J.E., Kolls J.K. CXCR3 and IFN protein-10 in Pneumocystis pneumonia. J Immunol 2006, 177:1846-1854.
39. Pepper M., Linehan J.L., Pagan A.J., Zell T., Dileepan T., Cleary P.P., Jenkins M.K. Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol 2010, 11:83-89.
40. Muranski P., Borman Z.A., Kerkar S.P., Klebanoff C.A., Ji Y., Sanchez-Perez L., Sukumar M., Reger R.N., Yu Z., Kern S.J., et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011, 35:972-985.
41. Haines C.J., Chen Y., Blumenschein W.M., Jain R., Chang C., Joyce-Shaikh B., Porth K., Boniface K., Mattson J., Basham B., et al. Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep 2013, 3:1378-1388.
42. Nakayamada S., Takahashi H., Kanno Y., O'Shea J.J. Helper T cell diversity and plasticity. Curr Opin Immunol 2012, 24:297-302.
43. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., Holman L.A., James E.R., Billingsley P.F., Gunasekera A., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
44. Lauvau G., Vijh S., Kong P., Horng T., Kerksiek K., Serbina N., Tuma R.A., Pamer E.G. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 2001, 294:1735-1739.
45. Bozza S., Gaziano R., Lipford G.B., Montagnoli C., Bacci A., Di Francesco P., Kurup V.P., Wagner H., Romani L. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002, 4:1281-1290.
46. Ito J.I., Lyons J.M., Hong T.B., Tamae D., Liu Y.K., Wilczynski S.P., Kalkum M. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 2006, 74:5075-5084.
47. Bozza S., Clavaud C., Giovannini G., Fontaine T., Beauvais A., Sarfati J., D'Angelo C., Perruccio K., Bonifazi P., Zagarella S., et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 2009, 183:2407-2414.
48. Cole G.T., Hurtgen B.J., Hung C.Y. Progress toward a human vaccine against Coccidioidomycosis. Curr Fungal Infect Rep 2012, 6:235-244.
49. Stevens D.A., Clemons K.V., Liu M. Developing a vaccine against aspergillosis. Med Mycol 2011, 49Suppl1:S170-S176.
50. Lin L., Ibrahim A.S., Xu X., Farber J.M., Avanesian V., Baquir B., Fu Y., French S.W., Edwards J.E., Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009, 5:e1000703.
51. Luo G., Ibrahim A.S., French S.W., Edwards J.E., Fu Y. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One 2011, 6:e25909.
52. Sandini S., La Valle R., Deaglio S., Malavasi F., Cassone A., De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 2011, 62:215-224.
53. Bromuro C., Romano M., Chiani P., Berti F., Tontini M., Proietti D., Mori E., Torosantucci A., Costantino P., Rappuoli R., et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010, 28:2615-2623.
54. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., Proietti C., Bistoni F., Cassone A., Vecchiarelli A. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007, 75:5085-5094.
55. Paulovicova E., Machova E., Tulinska J., Bystricky S. Cell and antibody mediated immunity induced by vaccination with novel Candida dubliniensis mannan immunogenic conjugate. Int Immunopharmacol 2007, 7:1325-1333.
56. Saville S.P., Lazzell A.L., Chaturvedi A.K., Monteagudo C., Lopez-Ribot J.L. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol 2009, 16:430-432.
57. Cutler J.E., Corti M., Lambert P., Ferris M., Xin H. Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus. PLoS One 2011, 6:e22030.
58. Tarcha E.J., Basrur V., Hung C.Y., Gardner M.J., Cole G.T. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun 2006, 74:516-527.
59. Chow S.K., Casadevall A. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 2011, 29:1891-1898.
60. Datta K., Lees A., Pirofski L.A. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol 2008, 15:1176-1187.
61. Specht C.A., Nong S., Dan J.M., Lee C.K., Levitz S.M. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 2007, 196:796-800.
62. Gomez F.J., Allendoerfer R., Deepe G.S. Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun 1995, 63:2587-2595.
63. Carvalho A., De Luca A., Bozza S., Cunha C., D'Angelo C., Moretti S., Perruccio K., Iannitti R.G., Fallarino F., Pierini A., et al. TLR3 essentially promotes protective class I-restricted memory CD8(+) T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood 2012, 119:967-977.
64. Ramadan G., Davies B., Kurup V.P., Keever-Taylor C.A. Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol 2005, 140:81-91.
65. Sun Z., Zhu P., Li L., Wan Z., Zhao Z., Li R. Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection. Eur J Clin Microbiol Infect Dis 2012, 31:3089-3096.
66. Potenza L., Vallerini D., Barozzi P., Riva G., Forghieri F., Beauvais A., Beau R., Candoni A., Maertens J., Rossi G., et al. Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients. PLoS One 2013, 8:e74326.
67. Deepe G.S. Role of CD8+ T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J Immunol 1994, 152:3491-3500.
68. Deepe G.S., Gibbons R.S. Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasma capsulatum. Infect Immun 2002, 70:3759-3767.
69. Zhou P., Freidag B.L., Caldwell C.C., Seder R.A. Perforin is required for primary immunity to Histoplasma capsulatum. J Immunol 2001, 166:1968-1974.
70. Wozniak K.L., Young M.L., Wormley F.L. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol 2011, 18:717-723.
71. Levitz S.M., Dupont M.P., Smail E.H. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun 1994, 62:194-202.
72. Hung C.Y., Castro-Lopez N., Cole G.T. Vaccinated C57BL/6 mice develop protective and memory T cell response to Coccidioides posadasii infection in the absence of IL-10. Infect Immun 2014, 82(February (2)):903-913.
73. Bernardino S., Pina A., Felonato M., Costa T.A., Frank de Araujo E., Feriotti C., Bazan S.B., Keller A.C., Leite K.R., Calich V.L. TNF-alpha and CD8+ T cells mediate the beneficial effects of nitric oxide synthase-2 deficiency in pulmonary paracoccidioidomycosis. PLoS Negl Trop Dis 2013, 7:1-18.
74. Burlandy-Soares L.C., Mamoni R.L., Lyra L., Schreiber A.Z., Blotta M.H. Expression of activation and cytotoxic molecules by peripheral blood lymphocytes of patients with paracoccidioidomycosis. Med Mycol 2010, 48:843-852.
75. McAllister F., Steele C., Zheng M., Shellito J.E., Kolls J.K. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 2005, 73:7450-7457.
76. Ghaleb M., Hamad M., Abu-Elteen K.H. Vaginal T lymphocyte population kinetics during experimental vaginal candidosis: evidence for a possible role of CD8+ T cells in protection against vaginal candidosis. Clin Exp Immunol 2003, 131:26-33.
77. Quimby K., Lilly E.A., Zacharek M., McNulty K., Leigh J.E., Vazquez J.E., Fidel P.L. CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis. Oral Dis 2012, 18:153-161.